# Tawee Tanvetyanon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tawee-tanvetyanon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,278 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 42 |
| i10-index | 91 |
| Last Known Institution | University of South Florida |
| OpenAlex ID | https://openalex.org/A5022912407 |
| ORCID iD | 0000-0002-1287-1757 |
| Works | 273 |

## Researcher papers

- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [Non–Small Cell Lung Cancer, Version 4.2024](https://scholariq.org/papers/non-small-cell-lung-cancer-version-4-2024/)
- [NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2023/)
- [Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial](https://scholariq.org/papers/tumor-infiltrating-lymphocyte-treatment-for-anti-pd-1-resistant-metastatic-lung/)
- [Outcomes of Adrenalectomy for Isolated Synchronous Versus Metachronous Adrenal Metastases in Non–Small-Cell Lung Cancer: A Systematic Review and Pooled Analysis](https://scholariq.org/papers/outcomes-of-adrenalectomy-for-isolated-synchronous-versus-metachronous-adrenal/)
- [Management of the adverse effects associated with intravenous bisphosphonates](https://scholariq.org/papers/management-of-the-adverse-effects-associated-with-intravenous-bisphosphonates/)
- [Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-i-ii-study-of-the-src-inhibitor-dasatinib-in-combination-with-erlotinib-in/)
- [Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/feasibility-and-efficacy-of-molecular-analysis-directed-individualized-therapy/)
- [Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer](https://scholariq.org/papers/prognostic-factors-for-survival-after-salvage-reirradiation-of-head-and-neck/)
- [Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/smoking-cessation-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)
- [Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer](https://scholariq.org/papers/real-world-safety-of-tarlatamab-step-up-dosing-in-extensive-stage-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Researcher university

- [University of South Florida](https://scholariq.org/institutions/university-of-south-florida/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.